From Nasdaq: 2025-02-18 12:35:00

Investors are closely eyeing NVIDIA as GPUs and AI gain popularity, with NVIDIA’s stock soaring 91.3% in the past year. The healthcare sector sees significant advancements in diagnostics and treatment, with NVIDIA’s platforms like BioNeMo and Clara leading the charge in drug discovery and medical imaging.

AI in healthcare is projected to reach $164.16 billion by 2030, growing at a CAGR of 49.1%. Cloud-based solutions are expected to witness high growth, improving data integration and accessibility. AI applications like predictive analytics and medical imaging integration are set to enhance operational efficiency and patient care.

Three healthcare stocks, Illumina, IQVIA, and Dexcom, are leveraging AI to drive innovation in genomics, clinical research, and diabetes management. Illumina partners with NVIDIA to optimize multiomic data analysis, while IQVIA focuses on enhancing patient outcomes with healthcare-grade AI. Dexcom integrates AI into glucose biosensing technology for improved diabetes management.

Illumina, with a Zacks Rank #3, expects earnings growth of 83.3% in 2025. IQVIA, also a Zacks Rank #3 company, aims to report earnings growth of 6.5% and 11.7% in 2025 and 2026, respectively. Dexcom, another Zacks Rank #3 stock, projects earnings growth of 20.7% and 21.6% in 2025 and 2026, respectively.

Investors can explore Zacks’ portfolio services for $1 to access stock picks with double- and triple-digit gains. With advancements in AI and GPUs, the healthcare sector is poised for unprecedented improvements in patient care and operational efficiency.



Read more at Nasdaq: NVIDIA’s Rise Puts These 3 Healthcare Stocks in the Spotlight